GTCB

[brucey]

1.12?real good price.
Congtats!Doyle!

[gambler2075]

Loaded the boat, all in today at what I thought was 1.00... actually filled at 0.99. (see 1,000,000$ board for my realtime post)

oversold capitulation today. They took advantage of a weak market as well.

Will likely get out tomorrow for a quick flip.

g

[D&Data]

was out.....
SHIT !

Watch...more  than 100 % in PM

• UPDATE - EU panel backs goat-derived drug after rethink
at Reuters (Fri 7:43am) 
• InPlay: GTC Biotherapeutics receives CHMP recommendation to grant mkt authorization
Briefing.com (Fri 7:14am) 
• ATryn(R) Receives CHMP Recommendation to Grant Market Authorization
Business Wire (Fri 7:12am) 

http://finance.yahoo.com/q?s=gtcb

[maverick12]

Me too . Sold yesterday after keeping for 2 months!!

[D&Data]

bwaaaaaaaaaaaaaaaa ha haha ahaaaaaaaa
--excuse me....but I can't resist laughing !!!! (it's too stupid!)

Too funny !....
pfffffff( what a shit! )

Sorry 4 us..
(my future rocket...and I'm still believing it...is INSM =clinical phase2 results end of june )
have a look :

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=1600811390&tid=insm&sid=1600811390&mid=102295

[maverick12]

I open and closed too many positions in INSM in past 6 months. To be honest, got tired of it. Either the market for the product is small or law suit is killing it. No good news is getting it up. I am out for good unless lawsuit is out of way

[D&Data]

yes....Sometimes to not saying every days.. I'm disgusted about it
but I've got the time..and my little finger says me that it will explode without telling us ( like GTCB lol )

[maverick12]

Good for you 

[ScottishTrader]

GTCB looks ready to break out of symmetric triangle today on this news:

GTC Biotherapeutics and LFB Biotechnologies Enter Strategic Collaboration for Recombinant Plasma Proteins and Monoclonal Antibodies
http://biz.yahoo.com/bw/061002/20061002005515.html?.v=1

Chart looks poised, buys coming in PM around 1.30, sugesting breakout.  Possibly one to watch this morning.

[ScottishTrader]

Picked up some GTCB on Mon morning at 1.33 as it was looking strong, but it topped out and died at descending resistance, eventually also managing to test support at 1.19.  Not a pretty day, but yesterday was slightly better, forming a nice hammer candle, although volume dropped off significantly.

Looks like there is a resistance band from 1.30-1.35 which may get tested again shortly.  Suggested stop would be 1.18, which leaves substantial risk from my entry point.  Although my initial reasoning for buying (breakthrough descending resistance on volume) didn't turn out as expected, GTCB held above the stepper descending resistance (now support), so will hold to see where this one goes this week.  It may have some strength yet...

[ScottishTrader]

Apparently some news for GTCB today, though not on yahoo yet:

TC BIOTHERAPEUTICS AWARDED $1.4 MILLION IN CONTINUED SBIR FUNDING FOR CD137 MONOCLONAL ANTIBODY PROGRAM

FRAMINGHAM, MA – October 5, 2006 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that it was awarded an additional grant of $1.4 million for its CD137 monoclonal antibody program from the Small Business Innovative Research, or SBIR, program of the National Institutes of Health. The first year committed funding is approximately $780,000. This grant will fund process development, characterization of the antibody and efficacy testing in preclinical models in anticipation of future manufacturing for clinical trials. GTC in-licensed the CD137 antibody from the Mayo Clinic and obtained initial SBIR funding in 2004. The work planned under this additional grant will be performed over two years in collaboration with Dr. Scott Strome at the University of Maryland and Dr. Lieping Chen at the Johns Hopkins School of Medicine.

"The CD137 antibody appears to have significant potential for the treatment of solid tumors and autoimmune diseases," stated Harry Meade, Ph.D., GTC's Senior Vice President of Research and Chief Scientific Officer. "We are gratified that the SBIR program recognized this potential and the further funding will enable us to continue our work in the preclinical evaluation of CD137's activity."

CD137, also known as 4-1BB, is a member of the tumor necrosis factor/nerve growth factor family of receptors and is a surface glycoprotein found on certain cells of the immune system.

The SBIR program is a source of federal government funding administered by various government agencies for domestic small business concerns to engage in research and development activities with the potential for commercial development.

[ScottishTrader]

Saying that, I really didn't like the look of yesterday's trading.  Chart is really more of a descending triangle.  LOD was 1.20, right around support.  Here's hoping it gets kicked into gear a bit here.  This is not a stock I want or intend to hold long term, and right now I think i would prefer to get out, limiting my losses.

[setravis]

bizjournals.com
GTC Biotherapeutics granted fast-track on vein therapy
Tuesday September 4, 2:06 pm ET


Federal regulators are granting GTC Biotherapeutics Inc. an expedited permitting process for its vein therapy treatment, the company announced on Tuesday.
Framingham, Mass.-based GTC (Nasdaq: GTCB - News) said that the U.S. Food and Drug Administration has granted fast-track designation for ATryn, a plasma treatment designed to combat hereditary antithrombin deficiency, which can lead to blood clotting.


Fast-track designation is given for treatments deemed to treat life threatening conditions for which no other comparable treatment exists. As part of the designation, GTC also gained the ability to submit its marketing approval application for ATryn as sections are completed rather than all at once, which should enable an FDA review to begin more quickly.

GTC said it expects to begin applying for marketing approval for the drug by its fourth quarter, completing the application process by the end of its fiscal 2008 first quarter.

ATryn is produced in the milk of goats engineered to have the human antithrombin gene, in order to generate a steady supply of the substance. GTC has already gained approval to use the drug in the European Union.

Published September 4, 2007 by the Boston Business Journal

[setravis]

"GTCB" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.                            
All history on a stock pick in 1 thread is awesome.                           
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.                   
Thank You....and good luck with all your trades....make some $$$               

[rdemp52572]

Anybody out there following GTCB?

It caught my eye Friday afternoon when it had a nice little pop late in the afternoon.
Rumors are starting about their meeting with the FDA on Jan 9th and was wondering if anyone here has any skinny on them?